Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations

Key Points

• This research aims to clarify viloxazine's pharmacological actions related to norepinephrine and serotonin receptors relevant to ADHD treatment.
• Conducted pharmacological experiments to assess norepinephrine transporter occupancy.
• Evaluated binding affinity of viloxazine at serotonin 5-HT2C, 5-HT2B, and 5-HT7 receptors.
• Measured receptor activity at clinically relevant concentrations for ADHD.
• Viloxazine shows high occupancy of norepinephrine transporters.
• Acts as a partial agonist at serotonin 5-HT2C receptors.
• Functions as an antagonist at 5-HT2B and 5-HT7 receptors, contributing to its therapeutic effects.